Which biotech stock has the best potential

**Moderna (MRNA)** has the best potential among the biotech stocks due to several factors:

1. **Recent FDA Approval and Upcoming Vaccine Launches**: Moderna recently gained FDA approval for its RSV vaccine, mResvia, for adults ages 60 and older on May 31, 2024. This approval is a significant milestone and could lead to substantial revenue. The company also plans to file for approvals of three other vaccines this year: a next-generation COVID-19 vaccine, a combination flu/COVID vaccine, and an RSV vaccine for adults ages 18 to 59. The potential of these vaccines is high, especially considering the ongoing need for COVID-19 and flu vaccines.
2. **Pipeline Progress**: Moderna has several pipeline programs that show promise. The late-stage study of mRNA-1647, a CMV vaccine, is expected to provide results by the end of the year. In addition, the company is evaluating mRNA-4157 in phase 3 testing as an adjuvant treatment for melanoma with Merck's Keytruda. If successful, these programs could lead to significant product approvals and revenue.
3. **Analyst Confidence**: Despite the recent drop in share price, analysts have set an average price target of $111.74 for Moderna, indicating a significant upside potential. The consensus rating for Moderna is "Neutral," which suggests that analysts do not have a strong buy or sell consensus.

4. **Market Position and Financial Health**: Moderna's market capitalization is substantial, which typically indicates a strong market position and financial stability. The company's focus on vaccine development, which has been proven successful, bodes well for its future prospects.
5. **Risk Considerations**: It's important to note that investing in biotech stocks always carries significant risk due to the uncertainty surrounding clinical trial outcomes and product approvals. However, Moderna's recent FDA approval and pipeline progress mitigate some of this risk, as these achievements demonstrate the company's capabilities and potential for future revenue streams.

In conclusion, while all biotech stocks inherently carry risk, Moderna's recent accomplishments and future pipeline potential make it a strong candidate for the best-performing biotech stock through 2030.